Merck allocates three million courses of Molnupiravir to be provided in first half of 2022 for use in LMICs Read more
Stempeutics gets DCGI nod for phase-III clinical trial on its product for treating COVID patients Read more
Strides Pharma’s Singapore arm gets US FDA nod for generic version of oseltamivir phosphate Read more